[Dec-2023] Get 100% Real Free RAC Regulatory Affairs Certification RAC-US Sample Questions
Accurate RAC-US Questions with Free and Fast Updates
The Regulatory Affairs Certification (RAC) is a globally recognized certification for regulatory professionals who work within the healthcare industry. RAC-US is one of the most prestigious certifications in the regulatory affairs field, and it is administered by the Regulatory Affairs Professionals Society (RAPS). The RAC-US certification exam is designed to test the candidate's knowledge of the US regulatory environment and their ability to apply that knowledge to real-world scenarios.
NEW QUESTION # 52
One month prior to the anticipated approval date for your product, the marketing application that you submitted to a major regulatory authority has become the subject of an advisory committee meeting of experts convened by the regulatory authority. The advisory committee members unanimously vote not to approve your product because of a safety concern. Two days after the advisory committee meeting, the regulatory authority requests additional information to support the safety of your product. Assuming you have no additional data to provide, which of the following would be your MOST appropriate response to the regulatory authority's request?
- A. "We have no additional information to provide at this time because we have already provided everything needed to support our product's approval."
- B. "We disagree with the advisory committee's decision because the committee neglected the thorough safety analysis that we provided."
- C. "Given the advisory committee's unanimous decision, we know that the product will not be approved, and additional data will not make any difference."
- D. "We have no additional information to provide at this time, but we can perform an additional analysis for a specific safety concern, if necessary."
Answer: D
NEW QUESTION # 53
You discover that your company's top selling product in the last two years has been used off-label.
The off-label use is estimated to be about 70%, and it has been consistent since the product was first released to the market. Which of the following is MOST appropriate?
- A. Advise the senior management to send a "Dear Dr." letter.
- B. File a report to regulatory authorities and advise the marketing department to prevent future off-label use.
- C. Discuss with regulatory authorities to investigate how to have the off-label indication approved.
- D. No action is required since it is an off-label use.
Answer: C
NEW QUESTION # 54
Following the introduction of a new regulation, an evaluation of the company's products by the regulatory affairs professional indicates that 60 percent do not comply with the regulation.
What should the regulatory affairs professional do FIRST to meet the new requirement?
- A. Request a permanent waiver from the new regulation.
- B. Contact the trade association for advice.
- C. Prepare documents for the files.
- D. Communicate with the relevant internal departments.
Answer: D
NEW QUESTION # 55
The API used for an approved drug product conforms to international monograph specifications and local pharmacopeia; however, the international monograph specifications of the API will be changing soon. Which is the most appropriate action for the regulatory affairs professional to take FIRST?
- A. Analyze the impact of the international monograph change on the local pharmacopeia.
- B. Transfer the notice of the upcoming international monograph change to QA for further processing.
- C. Prepare the international monograph change submission first and then prepare the local change when required.
- D. Confirm that the international monograph change is not related to local pharmacopeia.
Answer: B
NEW QUESTION # 56
Who has the PRIMARY responsibility for recall of products with quality defects?
- A. Consumer
- B. Distributor
- C. Manufacturer
- D. Regulatory authority
Answer: C
NEW QUESTION # 57
In order to develop a global drug product, what is the MOST important environmental characteristic to consider in the country of intended use?
- A. Product requirements
- B. Product formulation
- C. Product stability
- D. Product registration
Answer: C
NEW QUESTION # 58
A regulatory affairs professional is asked to review and update regulatory affairs SOPs.
Which aspect of the SOP Is MOST important to consider?
- A. Revision history
- B. Scope and level of detail
- C. Relevance to regulations
- D. Expiration date
Answer: C
NEW QUESTION # 59
A company is currently marketing an implantable orthopedic medical device. The R&D department is planning to change the material used for the implant. The R&D department states that the change does not impact the safety and effectiveness of the product.
What action should the regulatory affairs professional take FIRST?
- A. Prepare regulatory submissions that detail the medical device's change in materials.
- B. No action is needed in this situation.
- C. Review the content of change and supporting data for the equivalency with the current material.
- D. Write a memo to file since the change does not impact product safety and effectiveness.
Answer: C
NEW QUESTION # 60
According to ICH, how many stability time points are normally required to establish a two- year shelf life for a product?
- A. 0
- B. 1
- C. 2
- D. 3
Answer: D
NEW QUESTION # 61
In which section of the ICH Common Technical Document will the overview of clinical data appear?
- A. Module 4
- B. Module 2
- C. Module 1
- D. Module 3
Answer: B
NEW QUESTION # 62
Why is it necessary to run supplemental safety pharmacology studies?
- A. To evaluate potential adverse pharmacodynamics effects not addressed by the core battery
- B. To provide adverse reaction reports and the results of the statistical data to the regulatory authority
- C. To comply with regulatory authority requirements related to clinical studies
- D. To substitute the utilization of GLP
Answer: A
NEW QUESTION # 63
During an audit of a contract manufacturing facility by a potential client, the auditor requested to be left alone in the records room. The records room contains information on all products produced by the contract manufacturer.
Which action is MOST appropriate for the regulatory affairs professional to take?
- A. Deny the auditor access to the room and retrieve only the requested records.
- B. Allow the auditor accompanied access to the room to retrieve the records.
- C. Deny the auditor access to the room and records due to confidentiality concerns.
- D. Allow the auditor access to the room and records due to the current audit.
Answer: B
NEW QUESTION # 64
The manufacturer of an API was changed from Company X to Company Y during the late stage of a new drug development. Despite differences in the manufacturing processes of the companies, both APIs meet the current specifications. Which is the MOST appropriate information to include in the final submission documents?
- A. The process information and analytical result of Company X API
- B. Information deemed appropriate by the regulatory authority
- C. The process information and the comparative analytical result of APIs from both companies
- D. The process information and analytical result of Company Y API
Answer: C
NEW QUESTION # 65
A global company is developing a sophisticated implantable medical device that is coated with antibiotics and biologics to enhance its efficacy.
The product is marketed in Country X.
where it is regulated as a medical device.
The same product, without the antibiotics and biologics, is marketed as a medical device in Country Y.
The company is proposing to start marketing the coated device in Country Y.
Which regulatory approach should the company propose?
- A. Apply for review of the additional part of the product as a pharmaceutical product in Country
- B. Examine decisions made about similar products in Country Y to propose the classification of the product.
- C. Submit the product as a medical device in Country Y as the product is already marketed in Country X as a medical device.
- D. Submit the product for review as a pharmaceutical product in Country Y.
Answer: A
NEW QUESTION # 66
Which of the following is the PRIMARY purpose of an audit report?
- A. To carry out a complete review of product applications
- B. To train sales representatives
- C. To document compliance history
- D. To define how to prepare new product submissions
Answer: C
NEW QUESTION # 67
At the last internal audit, a regulatory affairs professional identified a need for a corrective action for the manufacturing process. Which of the following stakeholders should be notified FIRST?
- A. Regulatory agency
- B. Quality assurance
- C. Quality improvement
- D. Clinical affairs
Answer: B
NEW QUESTION # 68
A company is considering the development of a medical device similar to those already available. Which of the following should be evaluated FIRST when developing a clinical evaluation document?
- A. Literature search
- B. Clinical experience
- C. Clinical investigations
- D. Adverse event reports
Answer: C
NEW QUESTION # 69
The requirements for document control are located in which of the following documents?
- A. WHO guidelines
- B. IEC 60601
- C. ICH guidelines
- D. ISO 13485
Answer: D
NEW QUESTION # 70
Which of the following situations does NOT require rapid communication to regulatory authorities?
- A. A major safety finding from a newly completed animal carcinogenicity study
- B. A lack of efficacy with a medicinal product used in treating a life-threatening disease
- C. A clinically important increase in the rate of occurrence of an "expected." but serious
ADR - D. A statistically significant increase in the number of deaths in an animal dose finding study
Answer: C
NEW QUESTION # 71
A protocol for a pivotal registration trial of a new product is submitted to a major regulatory authority for review and approval. The regulatory authority issues the company a written commitment that if the studies are completed as outlined in the protocol and the results meet the pre-specified criteria for efficacy and safety, the product will be approved.
During the final week of the review of the marketing application, which has fully met all pre- specified criteria, the company receives a letter from the regulatory authority stating that it no longer believes that the product will be approved based on a recent withdrawal of a similar product in another country.
What is the BEST response?
- A. Notify the regulatory authority regarding Its obligation to honor the commitment to approve the application.
- B. Request a meeting with the regulatory authority to discuss the application.
- C. Consult with the legal department to discuss the best course of action.
- D. Review the regulatory guidelines to determine how to proceed.
Answer: B
NEW QUESTION # 72
Company X and Company Y both have products for the treatment of rare genetic diseases.
Company X would like to acquire Company Y but does not know enough about Company Y to make an offer.
What is the MOST appropriate approach that Company X should take to acquire more information about Company Y?
- A. Request the needed information from the Board of Directors of Company Y.
- B. Perform a thorough library search to gather detailed information on Company Y.
- C. Recruit a professional to gather confidential intelligence on Company Y.
- D. Enter into an agreement with Company Y to perform due diligence.
Answer: D
NEW QUESTION # 73
......
The Regulatory Affairs Certification (RAC) is a globally recognized certification program that aims to assess the knowledge and expertise of regulatory professionals in the pharmaceutical, medical device, and biotechnology industries. The RAC certification program is offered by the Regulatory Affairs Professionals Society (RAPS), which is a leading professional organization for regulatory affairs professionals. The RAC certification program is designed to demonstrate the proficiency of regulatory professionals in understanding and navigating the complex regulatory landscape in the healthcare industry.
RAC-US Study Guide Realistic Verified Dumps: https://www.exam4labs.com/RAC-US-practice-torrent.html
Self-Study Guide for Becoming an Regulatory Affairs Certification (RAC) US Expert: https://drive.google.com/open?id=1cSYbJf35ne-rC-7CVTAyoq7jI86QSoXH